ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
EU green light for Chiesi’s Lamzede
pharmatimes
July 18, 2018European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
Pharma Sources Insight January 2025
